Peptidylarginine deiminases (PADs) catalyse a post-translational modification of proteins through the conversion of arginine residues into citrullines. The existence of four isoforms of PAD (types I, II, III and IV) encoded by four different genes, which are distinct in their substrate specificities and tissue-specific expression, was reported in rodents. In the present study, starting from epidermis polyadenylated RNA, we cloned by reverse transcriptase-PCR a full-length cDNA encoding human PAD type I. The cDNA was 2711 bp in length and encoded a 663-amino-acid sequence. The predicted protein shares 75% identity with the rat PAD type I sequence, but displays only 50–57% identity with the three other known human isoforms. We have described the organization of the human PAD type I gene on chromosome 1p36. A recombinant PAD type I was produced in Escherichia coli and shown to be enzymically active. Human PAD type I mRNAs were detected by reverse transcriptase-PCR not only in the epidermis, but also in various organs, including prostate, testis, placenta, spleen and thymus. In human epidermis extracts analysed by Western blotting, PAD type I was detected as a 70 kDa polypeptide, in agreement with its predicted molecular mass. As shown by immunohistochemistry, the enzyme was expressed in all the living layers of human epidermis, with the labelling being increased in the granular layer. This is the first description of the human PAD type I gene and the first demonstration of its expression in epidermis.

Key words: citrulline, deimination, enzyme, epidermis, post-translational modification.

INTRODUCTION

Post-translational modifications of proteins are involved in many cellular events, including signal transduction, gene expression and differentiation. One of these modifications is protein deimination, which corresponds to the conversion of their arginine residues into citrullines (for review, see [1]). This results in a decrease in the net charge of the proteins and probably in modifications of their function. For example, in vitro deimination of specific arginine residues has been shown to modify the functional properties of trypsin inhibitor [2], intermediate filament proteins [3], glycogen phosphorylase [4], and calcineurin [5], but the physiological role of these modifications remains to be explored. Citrullines were first demonstrated in hair follicles [5], but the physiological role of these modifications remains to be explored. Citrullines were first demonstrated in hair follicles [5], but the physiological role of these modifications remains to be explored. Citrullines were first demonstrated in hair follicles [5], but the physiological role of these modifications remains to be explored. Citrullines were first demonstrated in hair follicles [5], but the physiological role of these modifications remains to be explored. Citrullines were first demonstrated in hair follicles [5], but the physiological role of these modifications remains to be explored.
but appear to have different tissue-specific expression as shown by reverse transcriptase (RT)-PCR and/or Northern-blot analysis: PAD type I mRNA is detected in mouse epidermis and uterus [32] and in rat epidermis and stomach [33], whereas PAD type III is mainly detected in epidermis and hair follicles [29]; PAD types II and IV were found to be expressed more widely, for example, in epidermis, stomach, skeletal muscle, brain, ovary, uterus and salivary glands [27,31,33]. Although transcripts of all four types of PAD were detected in newborn rodent epidermis, to date only PAD type I and III proteins have been identified in epidermal extracts [26,29]. In sheep, PAD type III mRNA was detected in hair follicles, but not in epidermis, suggesting that regulation of PAD expression varies between species [24]. Concerning human tissues, three types of PAD have been cloned to date, i.e. PAD type II (GenBank accession number AB030176), PAD type III [34] and PAD type V [35], which is closely related to the rodent type IV. The tissue specificity of the human PADs is poorly known. PAD type II was immunodetected in sweat glands [36]. PAD type III was strongly immunodetected in both the inner and outer root sheaths of hair follicles and only weakly in all the cellular layers of the interfollicular epidermis, with the exception of the cornified layer [34]. PAD type V was found in blood eosinophil and neutrophil polymorphonuclear cells [37]. Virtually no data are available regarding the sequence and tissue expression of human PAD type I, although the data obtained in rodents suggest it is present in the epidermis.

In the present study, the full-length cDNA of human PAD type I was cloned from epidermis, its gene organization determined and its tissue expression analysed. Moreover, an active recombinant enzyme was produced in bacteria. Generation of peptide-specific antibodies against PAD type I allowed its expression in human epidermis to be demonstrated.

EXPERIMENTAL

Cloning of human PAD type I cDNA

A plastic surgery specimen of normal human skin (kindly provided by Professor J.-P. Chavoin, Service de Chirurgie Plastique, Centre Hospitalier Universitaire Rangueil, Toulouse, France) was cut into thin fragments and incubated promptly for 2 h at 37 °C in a 0.25% trypsin solution (Life Technologies). Epidermis was dissected with forceps and gently rinsed in PBS. Purification of mRNA was performed using oligo(dT)20 magnetic beads according to the manufacturer’s instructions (Dynal). cDNA was synthesized by random priming with the SuperScript kit (Life Technologies) starting with approx. 80 ng of mRNA. PCR amplification of the central region of human PAD type I cDNA was performed with primers derived from the PAD type I rat sequence (nt 1007–1025 and 1911–1932; GenBank accession number AB010998). The PCR product was cloned into the pCR2.1-TOPO vector (Invitrogen), sequenced and internal gene-specific primers were designed for rapid amplification of cDNA ends (RACE) cloning. The SMART™ RACE cDNA amplification kit (Clontech) was used, according to the manufacturer’s instructions, to clone both 5′- and 3′-ends of the cDNA, starting from total RNA extracted from human epidermis (obtained as described above) using a standard guanidine method. RT reactions were performed by oligo(dT) priming of 1 μg of total RNA. PCR amplifications were carried out with one fortieth of an RT reaction and random primers. The PCR conditions were as follows: 94 °C for 10 s, followed by 28 or 34 cycles at 94 °C for 25 s, 60 °C for 20 s, and 72 °C for 40 s and a terminal extension period (72 °C for 5 min). The PCR products were separated on 2% agarose/TBE [where TBE is 89 mM Tris, 89 mM borate, pH 8.3 and 2 mM EDTA] gels. Glyceraldehyde-3-phosphate dehydrogenase primers were used in PCR control reactions to confirm the normalization of the cDNAs provided by Clontech.

Antibodies

The anti-GST monoclonal antibody was purchased from Pierce. The ascites fluid of MOPC-21 (Sigma) was used as a negative control. Anti-peptide antibodies directed against human PAD type I were produced in rabbits by injecting synthetic peptides conjugated via an added N-terminal cysteine residue to keyhole-limpet (Diodora aspera) haemocyanin. The peptides used were synthesized according to the predicted amino acid sequence of human PAD type I as follows: peptide A, CMAP-KRVVQLSLKM (amino acids 1–13); peptide B, CNHRS-EPDPTHWLM (amino acids 158–172); and peptide C, CARGGNSLDYKQ (amino acids 215–227) (where single-letter amino-acid notation has been used). Anti-peptide antibody titres were determined by ELISA (CovalAb, Lyon, France). The antisera were affinity-purified on a mixture of the three peptides coupled to an agarose-activated affinity column (Sulfolink™ kit), essentially as described by the manufacturer (Pierce).
Protein electrophoresis and immunoblotting

Rabbit muscle PAD type II was purchased from Sigma, and recombinant human PAD types III and V were generously provided by Professor H. Takahara (Department of Applied Biological Resource Science, School of Agriculture, Ibaraki University, Ibaraki, Japan) and Professor M. Yamada (Graduate School of Integrate Science, Yokohama City University, Yokohama, Japan) respectively. Dermo-epidermal cleavage of normal human skin was performed by heat treatment, and epidermal proteins were extracted in TENP-40 buffer [40 mM Tris/HCl buffer (pH 7.5) and 10 mM EDTA containing 0.5 % Nonidet P40 and protease inhibitors]. Proteins were separated by SDS/PAGE and either stained with Coomassie Blue or electrotransferred on to reinforced nitrocellulose membranes and probed with antibodies. The anti-GST monoclonal antibody and MOPC-21 were diluted to 0.1 µg/ml. Affinity-purified anti-peptide antibodies directed against human PAD type I were diluted to 0.46 or 0.11 µg/ml. For adsorption experiments, the antibodies were preincubated for either 30 min at 37 °C with peptides diluted to 20 µg/ml or overnight at 4 °C with recombinant human PAD type I transferred on to a nitrocellulose membrane. For the detection of deaminated proteins, citrulline residues of proteins transferred on to the membrane were chemically modified by overnight incubation at 37 °C in modification medium (0.0125 %, FeCl₃, 2.3 M H₂SO₄, 1.5 M H₃PO₄, 0.25 %, diacetyl monoxime, 0.125 %, antipyrine and 0.25 M acetic acid). The membrane was then incubated with antibodies specific to modified citrulline diluted to 0.125 µg/ml as reported previously [7,8]. Immunoreactivities were revealed using the ECL™ Western blotting kit as described by the manufacturer (Amersham Biosciences).

Immunohistochemistry

Immunohistochemistry was performed on Bouin’s fixed samples of breast skin embedded in paraffin using the peroxidase-labelled streptavidin–biotin amplification method and on cryosections of breast skin using indirect immunofluorescence. The anti-peptide antibodies directed against human PAD type I and purified by affinity chromatography, as described above, were diluted to 20 µg/ml (immunofluorescence) or 4.6 µg/ml (streptavidin–biotin amplification method).

RESULTS AND DISCUSSION

Cloning of the human PAD type I cDNA

To amplify cDNA from human epidermis, we used two rat PAD type I-specific primers that had a high sequence identity with the mouse orthologue, but low identity with the other rodent PAD types. After cloning the PCR products, sequencing revealed two different inserts. One corresponded to human PAD type II, which we have deposited in the DNA databases during the course of this study (GenBank® accession number AB030176). The other insert was 81 % identical with the rat and mouse PAD type I sequences, but only 68, 70 and 72 % identical with the human PAD types II III, and V respectively, as shown using Blast [38]. RACE-PCR was used to complete the human PAD type I cDNA. The full-length cDNA was 2711 bp in length and contained an open reading frame encoding a polypeptide of 663 amino acids with a calculated molecular mass of 74.6 kDa. The cDNA also consisted of a 5′-untranslated region of 83 bp and a 3′-untranslated region of 639 bp. During the course of the present study, a cDNA sequence encoding the human PAD type I was deposited in GenBank® (accession number AK026652). It essentially differs from the cDNA we obtained in the 3′-untranslated region, which is 1156 nt longer, corresponding to the use of an alternative polyadenylation site. Sequence comparison of the predicted protein revealed 76 % and 75 % identity with the mouse and rat PAD type I respectively (Figure 1A). A lower degree of identity (52–57 %) was observed with the other human PADS. More conserved regions were noted in the C-terminal region of all the murine and human PADS, supporting the hypothesis that this region is involved in the catalytic sites of the enzymes. In particular, His²⁷² and Cys³⁸³, two residues suggested previously as catalytic residues of the murine PAD type II [30], are conserved in the other cloned PAD sequences, including human PAD type I. Using the SignalP v1.1 program [39], no signal peptides or transmembrane regions were predicted, suggesting an intracellular location for the human PAD type I. A phylogenetic analysis suggested that the four human, rat and mouse PAD paralogues arose through a series of gene duplication events prior to divergence of these species, and confirmed that the human PAD type V is closely related to the murine PAD type IV (Figure 1B).

Determination of human PAD type I gene organization

A BLAT search at the Golden Path University of California at Santa Cruz web site (http://genome.cse.ucsc.edu) revealed that the four human PAD genes are located within a 300 kb region on chromosome 1p36.13. In agreement with our phylogenetic analysis, the genes of PAD types I, III and V are very close to each other and are included within a 160 kb region. Also, they are transcribed in the same orientation. Moreover, the transcribed regions of PAD types I and III are only 4 kb apart. In contrast, the PAD type II gene, transcribed in the opposite direction, is in a centromeric position 86 kb away (Figure 1C). Alignment of the human PAD type I cDNA and genomic sequences revealed that the entire cDNA sequence is covered over a range of 39.7 kb (GenBank® accession number NT_004401). The human PAD type I gene consists of 16 relatively short exons (ranging from 63–851 bp) interrupted by 15 intronic sequences from 104 bp to 639 bp, as expected from the recently published [42] genomic organization and the recent cloning of the human PAD type V [43]. The sequence of the human PAD type I gene consists of 16 exons (ranging from 63–851 bp) interrupted by 15 intronic sequences from 104 bp to 639 bp, as expected from the recently published [42] genomic organization and the recent cloning of the human PAD type V [43]. Judging from the recently published [42] genomic organization and the recent cloning of the human PAD type V [43].

Production of a recombinant human PAD type I

To express the cloned human PAD type I cDNA as a GST-fusion protein in E. coli, the entire coding sequence of the human PAD type I cDNA was cloned into the pGEX-6P vector. When IPTG-induced bacterial lysates were analysed by Western blotting with an anti-GST monoclonal antibody, a protein of 100 kDa was specifically immunodetected (results not shown). To demonstrate PAD activity, IPTG-induced bacterial lysates were incubated in the presence of 10 mM CaCl₂ in order to promote deamination of proteins by the recombinant fusion protein. Deaminated proteins in the incubated lysates were then immunodetected with the antibodies specific to modified citrulline after chemical modification of citrulline residues, as described in the Experimental section. As shown in Figure 2 (lane 3), numerous deaminated bacterial proteins over a broad range of molecular masses were detected, demonstrating the presence of PAD activity in the induced lysates. In both non-induced and IPTG-induced bacterial lysates incubated without CaCl₂, no deaminated proteins were detected (Figure 2, lanes 1 and 2). In addition, E. coli transformed with pGEX–hPADIr, containing the human PAD
Figure 1  Alignment of human and rodent PAD type I (A), phylogenetic analysis of human and rodent PADs of different types (B), and representation of the human PAD gene locus (C)

(A) Comparison of the predicted amino acid sequences of mouse (m), rat (r) and human (h) PAD type I. Solid and shaded backgrounds indicate identical or similar (R/K/H, A/S/T, I/L/V/M/C/F/Y/W, G/P and E/D/Q/N; where single-letter amino-acid notation has been used) amino acids respectively. For each PAD, the total number of amino acid residues is indicated in brackets. Solid (’) indicate the positions corresponding to exon–intron boundaries. The underlined sequences of human PAD type I correspond to the regions used to generate antibodies specific for the enzyme.

(B) A phylogenetic tree was generated from a multiple sequence alignment of the entire amino acid sequences using the Multalin program [40]. Distances were calculated according to Dayhoff’s
Table 1 Exon–intron organization of the human PAD type I gene

The numbers in the 3′ boundary and 5′ boundary columns indicate the location of the amino acid residues and nucleotides. Single-letter amino-acid notation is used.

<table>
<thead>
<tr>
<th>Exon no.</th>
<th>Exon size (bp)</th>
<th>Intron size (bp)</th>
<th>Sequence of exon–intron junctions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>175</td>
<td>18978</td>
<td>I H S A G... TCTCACGAG G... V D...</td>
</tr>
<tr>
<td>2</td>
<td>181</td>
<td>1150</td>
<td>D F H... K... V... R... V...</td>
</tr>
<tr>
<td>3</td>
<td>73</td>
<td>673</td>
<td>G V D... A... G... T... A...</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>1382</td>
<td>G... G G... G... A... A...</td>
</tr>
<tr>
<td>5</td>
<td>118</td>
<td>104</td>
<td>L A... D... T... L... Q...</td>
</tr>
<tr>
<td>6</td>
<td>126</td>
<td>2466</td>
<td>A R... G... G... T... C... L...</td>
</tr>
<tr>
<td>7</td>
<td>173</td>
<td>150</td>
<td>D P... G... C... C... T... L...</td>
</tr>
<tr>
<td>8</td>
<td>104</td>
<td>1033</td>
<td>V C... R... T... V... M...</td>
</tr>
<tr>
<td>9</td>
<td>124</td>
<td>363</td>
<td>W I... Q... G... G... E... M...</td>
</tr>
<tr>
<td>10</td>
<td>108</td>
<td>2139</td>
<td>R G... L... G... G... A... A...</td>
</tr>
<tr>
<td>11</td>
<td>152</td>
<td>4343</td>
<td>F P... K... D... E... R...</td>
</tr>
<tr>
<td>12</td>
<td>145</td>
<td>1157</td>
<td>D Q... K... G... G... F... R...</td>
</tr>
<tr>
<td>13</td>
<td>94</td>
<td>994</td>
<td>GAC CAG... AAG... A... G...</td>
</tr>
<tr>
<td>14</td>
<td>80</td>
<td>851</td>
<td>H A... Q... K... C...</td>
</tr>
<tr>
<td>15</td>
<td>126</td>
<td>3249</td>
<td>P D... M... G... C...</td>
</tr>
<tr>
<td>16</td>
<td>851</td>
<td></td>
<td>TAGA AAAAAA...</td>
</tr>
</tbody>
</table>

Type I cDNA in the reverse direction, had no PAD activity (results not shown). We next measured the activity of the IPTG-induced bacterial lysate towards two synthetic substrates, benzoyl-L-arginine ethyl ester (BAEE) and benzoyl-L-arginine (Bz-L-Arg). Activities against both substrates were rather low (0.123 and 0.118 unit/ml respectively) when compared with similar lysates of bacteria expressing GST–rat PAD type I (0.811 and 0.920 unit/ml respectively) or GST–human PAD type II (1.750 and 0.400 unit/ml respectively). However, the substrate specificity of the recombinant human PAD type I was similar to that of the recombinant rat PAD type I and clearly differentiated these enzymes from PADDs of other types, recombinant or native (Table 2). Attempts to purify the recombinant human enzyme in an active form were unsuccessful, because it unexpectedly lost its activity for unknown reasons. It might be either denatured or unfolded during the purification steps.

Analysis of PAD type I mRNA expression in human tissues

cDNAs of human MTC panels were used as PCR templates to study the expression of PAD type I in adult tissues. A representative amplification after 34 cycles is shown in Figure 3. Besides expression in epidermis, high levels of PAD type I mRNA were detected in prostate, testis, placenta, spleen and thymus. Colon, lung, liver and pancreas expressed intermediate levels of PAD type I mRNA. Very low levels or no signals were obtained in ovary, brain, peripheral blood leucocytes, small intestine, heart, skeletal muscle and kidney.

A Blast search of the GeneBank expressed sequence tag entries with the human PAD type I cDNA sequence revealed several expressed sequence tags from human (three from uterus, two from pancreas and two from colon), rat (three from eye) and mouse (including thymus, uterus, skin and vaginal epithelium) tissues, confirming that PAD type I is not skin-specific, but is expressed more widely.

Characterization and localization of human PAD type I in epidermis

Anti-peptide antibodies to human PAD type I were developed against three peptides corresponding to regions that differ

© 2003 Biochemical Society
Table 2 Comparison of substrate specificity of recombinant human PAD type I with other PADs

<table>
<thead>
<tr>
<th>PADs</th>
<th>Relative activity (%)</th>
<th>BAEE</th>
<th>Bz-L-Arg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant human PAD type I (bacterial extract)</td>
<td>100.0</td>
<td>95.9</td>
<td></td>
</tr>
<tr>
<td>Recombinant rat PAD type I*</td>
<td>100.0</td>
<td>114.3</td>
<td></td>
</tr>
<tr>
<td>Rat muscle PAD type I†</td>
<td>100.0</td>
<td>18.5</td>
<td></td>
</tr>
<tr>
<td>Recombinant human PAD type II‡ (bacterial extract)</td>
<td>100.0</td>
<td>22.9</td>
<td></td>
</tr>
<tr>
<td>Recombinant human PAD type III‡</td>
<td>100.0</td>
<td>19.7</td>
<td></td>
</tr>
<tr>
<td>Recombinant rat PAD type IV*</td>
<td>100.0</td>
<td>17.5</td>
<td></td>
</tr>
<tr>
<td>Recombinant human PAD type V§,¶</td>
<td>100.0</td>
<td>152.6</td>
<td></td>
</tr>
</tbody>
</table>

Data from Ishigami et al. [31]*; Watanabe et al. [22]; A. Ishigami (unpublished work); Kanno et al. [34]; and Nakashima et al. [35].

between PAD type I and the other types of PAD, as described in the Experimental section. The reactivity of the sera was tested by ELISA against each of the three peptides. The sera reacted predominantly with the peptide corresponding to residues 158–172, but not with the peptide corresponding to residues 1–13 (Figure 4A). The antisera were affinity-purified on a mixture of the three peptides and the specificity of the affinity-purified anti-peptide antibodies was demonstrated by immunoblotting human PAD type I recombinant protein produced in E. coli and by adsorption experiments (Figure 4B, lanes 1–6). The antibodies immunodetected neither rabbit PAD type II nor recombinant human PAD types III and V (results not shown).

The antibody reactivity was then investigated by immunoblotting proteins extracted from human breast epidermis. The affinity-purified antibodies detected a 70 kDa protein. The reactivity was specific, as it was blocked after absorption of the antibodies by recombinant human PAD type I (Figure 4B, lanes 7–9). Moreover, the protein was not detected when non-immune serum or unrelated rabbit antibodies were used (results not shown).

To localize human PAD type I precisely in epidermis, unfixed cryosections of human skin fragments as well as sections of Bouin’s-fixed skin were immunohistochemically analysed using the affinity-purified antibodies. On both unfixed (Figures 5A and B) and fixed skin (Figure 5C), the antibodies showed cytoplasmic keratinocyte labelling in all the epidermis living layers, the labelling intensity being higher in the upper spinous and granular layers. On parallel control sections incubated in the absence of primary antibody, no significant immunoreactivity was observed. Moreover, the reactivity decreased sharply or even disappeared after adsorption of the purified serum on recombinant human PAD type I (results not shown).

In human epidermis, PAD type III was also shown to be expressed in all the nucleated cell layers [34]. This distribution of PADs from basal to the cornified layer in the epidermis is in striking contrast with the distribution of deiminated proteins. Indeed, using antibodies specific for modified citrullines, virtually all deiminated proteins were found to be located in the cornified layer [7,8,43]. The lack of detection of PAD types I and III in the cornified layer is most probably due to masking of epitopes, as often observed with epidermal proteins, although deimination by other PAD types cannot be fully excluded. The presence of PADs in the lower epidermis could also indicate that PAD types...
Figure 4 Immunodetection of PAD type I in human epidermis as a 70 kDa protein

(A) Anti-peptide serum directed against human PAD type I was tested by ELISA against each of the peptides used for its production (amino acids 1–13, 158–172 and 215–227) as indicated. (B) E. coli cells transformed with pGEX–hPADI were induced in the absence (lane 2) or presence of IPTG (lanes 1, 3–6). Bacterial extracts were then immunodetected with an anti-GST monoclonal antibody (lane 1), affinity-purified anti-peptide antibodies directed against human PAD type I diluted to 0.11 μg/ml (lane 2 and 3), and the antibodies preadsorbed with peptides 1–13, 158–172 or 215–227 respectively (lanes 4–6). A TENP-40 extract of human epidermis was immunodetected in the absence of rabbit antiserum (lane 7), in the presence of the affinity-purified anti-peptide antibodies directed against human PAD type I diluted to 0.46 μg/ml (lane 8), and the antibodies preadsorbed with the recombinant human PAD type I (lane 9). The position of molecular-mass markers (in kDa) is indicated on the left.

I and III are kept inactive in the lower epidermis and activated later during differentiation. They could be activated by the calcium gradient that exists between the lower and the upper epidermis [44], as has been described for several other epidermal proteins [45]. Alternatively, substrate conformation or accessibility may be involved.

The expression of both PAD types I and III in human epidermis raises other questions, including why are several PAD isoforms expressed in the same tissue and even in the same cells, and do they act on the same targets? Since this process has already been shown to be disturbed in psoriatic epidermis [46], what about epidermis protein deimination in various other cutaneous diseases? The availability of the recombinant enzyme and specific antibodies described in the present study, in combination with the antibodies specific to modified citrullines, will be useful in answering these questions, permitting the biological role of human PAD type I to be studied first in normal and then in diseased epidermis.

We thank Professor H. Takahara and Professor M. Yamada for generously providing recombinant PAD types III and V respectively. We also thank Professor J.-P. Chavoin for providing us with normal human skin, and J. Henry for her valuable advice on using the Phylip Package. This study was supported in part by grants from the Université Paul Sabatier-Toulouse III, from INSERM (CJF 96-02), and from the Association pour la Recherche sur la Polyarthrite.

REFERENCES

Received 5 June 2002/18 October 2002; accepted 5 November 2002
Published as BJ Immediate Publication 5 November 2002, DOI 10.1042/BJ20020870


© 2003 Biochemical Society